Balance Sheet Components |
Balance Sheet Components
Cash Equivalents and Available-for-sale Securities
Cash equivalents and available-for-sale securities consisted of the following (in thousands): | | | | | | | | | | | | | | | | | | June 30, 2017 | | Amortized Cost | | Gross Unrealized | | | | Gains | | Losses | | Fair Value | Money market funds | $ | 9,236 |
| | $ | — |
| | $ | — |
| | $ | 9,236 |
| Corporate bonds | 15,839 |
| | — |
| | (18 | ) | | 15,821 |
| Commercial paper | 1,200 |
| | — |
| | — |
| | 1,200 |
| Government bonds | 37,163 |
| | — |
| | (57 | ) | | 37,106 |
| Total cash equivalents and available-for-sale securities | $ | 63,438 |
| | $ | — |
| | $ | (75 | ) | | $ | 63,363 |
| Classified as: | | | | | | | | Cash equivalents | | | | | | | $ | 9,236 |
| Available-for-sale securities - current | | | | | | | 54,127 |
| Available-for-sale securities - noncurrent | | | | | | | — |
| Total cash equivalents and available-for-sale securities | | | | | | | $ | 63,363 |
|
| | | | | | | | | | | | | | | | | | December 31, 2016 | | Amortized Cost | | Gross Unrealized | | | | Gains | | Losses | | Fair Value | Money market funds | $ | 11,270 |
| | $ | — |
| | $ | — |
| | $ | 11,270 |
| Corporate bonds | 21,886 |
| | — |
| | (45 | ) | | 21,841 |
| Commercial paper | 10,769 |
| | — |
| | — |
| | 10,769 |
| Government bonds | 41,316 |
| | 2 |
| | (29 | ) | | 41,289 |
| Total cash equivalents and available-for-sale securities | $ | 85,241 |
| | $ | 2 |
| | $ | (74 | ) | | $ | 85,169 |
| Classified as: | | | | | | | | Cash equivalents | | | | | | | $ | 18,504 |
| Available-for-sale securities - current | | | | | | | 56,515 |
| Available-for-sale securities - noncurrent | | | | | | | 10,150 |
| Total cash equivalents and available-for-sale securities | | | | | | | $ | 85,169 |
|
All available-for-sale securities - current held as of June 30, 2017 and December 31, 2016 had contractual maturities of less than one year. All available-for-sale securities - noncurrent held as of December 31, 2016 had contractual maturities of at least one year but less than two years. There were no available-for-sale securities - noncurrent held as of June 30, 2017. There have been no material realized gains or losses on available-for-sale securities for the periods presented.
Accrued Expenses and Other Payables
Accrued expenses and other payables consisted of the following (in thousands): | | | | | | | | | | June 30, 2017 | | December 31, 2016 | Accrued clinical and research related expenses | $ | 4,299 |
| | $ | 3,617 |
| Accrued employee related expenses | 1,338 |
| | 1,420 |
| Accrued professional service fees | 669 |
| | 115 |
| Accrued milestone payment to former collaboration partner | 250 |
| | — |
| Other | 171 |
| | 120 |
| Total accrued expenses and other payables | $ | 6,727 |
| | $ | 5,272 |
|
|